Zenobia Therapeutics has announced a strategic partnership to provide Alzheimer’s Drug Discovery Foundation researchers access to Zenobia’s discovery platform. The Zenobia platform includes a gene-to-structure platform with in-house cloning, expression and purification in E coli, insect and mammalian cells, a custom fragment library composed of diverse cores suitable for discovery of lead compounds that cross the blood-brain barrier, fragment screening by multiple validated methods and assay development. Zenobia will also provide access to their internal medicinal chemistry assets to optimize the fragments to leads that are potent, selective and optimized for CNS ADME/PK properties.
Zenobia Therapeutics signs strategic partnership with the Alzheimer’s Drug Discovery Foundation
Filed under alliances
